Viridian is currently investigating a portfolio of potentially transformative anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibodies for the treatment of thyroid eye disease (TED). IGF-1R, a transmembrane receptor that plays a role in development, metabolism, and immune regulation, is a clinically and commercially validated target for the treatment of TED. Based on work in the field, IGF-1R and the co-located thyroid stimulating hormone receptor (TSHR) have been found to play a key role in the pathogenesis of TED. Viridian is making meaningful progress advancing potentially improved anti-IGF-1R antibodies for people affected by TED and expects its intravenous (IV) and subcutaneous (SC) programs to be transformative treatment options for patients.

Approved Anti-IGF-1R AntibodyVRDN-001 IVVRDN-003 SC

Intravenous Infusion


Partial Antagonist

Phase of Development


Treatment Regimen

8 infusions, given three weeks apart with 60 to 90 minute infusion time

TED Program Details

Viridian’s lead product candidate, VRDN-001, is a potential best-in-class, IV monoclonal antibody targeting IGF-1R. VRDN-001 acts as a full antagonist of IGF-1R, and based on clinical data to date, has demonstrated robust clinical activity and was generally well-tolerated at Week 6 compared with the currently approved anti-IGF-1R antibody.1

The company is running two global Phase 3 trials, THRIVE (NCT05176639) and THRIVE-2 (NCT06021054), for people living with active and chronic TED, respectively.

1 Conclusions are not based on head-to-head clinical trial results.


VRDN-003 is a potential best-in-class subcutaneous anti-IGF-1R program in development for TED. VRDN-003 has the same binding domain as its parent molecule, VRDN-001, and was engineered to have a longer half-life. VRDN-003 is designed to maintain the clinical response of VRDN-001 IV while significantly increasing patient convenience and potentially improving safety.

Viridian is on track to initiate two phase 3 clinical trials of VRDN-003 in August 2024.


TED Program Quote

Previous Next